GKOS

1 Day 1D

5 Days 5D

1 Month 1M

6 Months 6M

YTD YTD

1 Year 1Y

5 Years 5Y

About Glaukos Corporation

Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. The company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. Glaukos launched the iStent, its first MIGS device, in the United States in 2012, its next-generation iStent inject device in the United States in 2018, and most recently, the iStent inject W device in 2020. In corneal health, Glaukos' proprietary suite of single-use, bio-activated pharmaceuticals are designed to strengthen, stabilize and reshape the cornea through a process called corneal collagen cross-linking to treat corneal ectatic disorders and correct refractive conditions. Glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of micro-scale surgical and pharmaceutical therapies in glaucoma, corneal health and retinal disease.
CEO
Thomas Burns
Employees
653
Headquarters

229 Avenida Fabricante
San Clemente, California 92672-7531
Phone: 19493679600
www.glaukos.com

News

Analog Devices To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Thursday
Feb 22, 2024 12:23pm

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page . Piper Sandler raised the price target for Wix.com Ltd. (NASDAQ: WIX ) from $146 to $165. Piper Sandler analyst Clarke Jeffries maintained an Overweight rating. Wix.com shares rose 5.9% to close at $132.77 on Thursday. See how other analysts view this stock. Keybanc boosted Analog Devices, Inc. (NASDAQ: ADI ) price target from $220 to $230. Keybanc analyst John Vinh maintained an Overweight rating. Analog Devices shares gained 2.3% to close at $193.72 on Wednesday. See how other analysts view this stock. Needham raised the price target for Glaukos Corporation (NYSE: GKOS ) from $105 to $108. Needham analyst David Saxon maintained a Buy rating. Glaukos shares rose 0.7% to close at $92.79 on Wednesday. See how other analysts view this stock . TD Cowen raised Wingstop Inc. (NASDAQ: WING ) … Full story available on Benzinga.


Source:Benzinga
Glaukos Corporation (GKOS) Q4 2023 Earnings Call Transcript
Feb 22, 2024 04:13am

No summary available.


Source:Seeking Alpha
Glaukos Corp (GKOS) Reports Increased Sales but Widening Losses in Q4 and Full Year 2023
Feb 21, 2024 21:35pm

Glaukos Corp (GKOS) Reports Increased Sales but Widening Losses in Q4 and Full Year 2023


Source:GuruFocus
Glaukos Quarterly Summary: Performance Insights and Disclosures
Feb 21, 2024 21:24pm

Glaukos (GKOS) has released an update. Glaukos Corporation has released a comprehensive Quarterly Summary for Q4 and the fiscal year ending Decembe…


Source:TipRanks
Glaukos Corp at JPMorgan Healthcare Conference Transcript
Feb 10, 2024 14:23pm

Glaukos Corp at JPMorgan Healthcare Conference Transcript


Source:GuruFocus
Glaukos Corp to Discuss the FDA Approval of iDose TR Transcript
Feb 10, 2024 14:23pm

Glaukos Corp to Discuss the FDA Approval of iDose TR Transcript


Source:GuruFocus
Glaukos Corp at Stifel Healthcare Conference Transcript
Feb 10, 2024 14:23pm

Glaukos Corp at Stifel Healthcare Conference Transcript


Source:GuruFocus
Q‘ —…—‘ Glaukos Corp Earnings Call Transcript
Feb 10, 2024 14:23pm

Q3 2023 Glaukos Corp Earnings Call Transcript


Source:GuruFocus
Glaukos Corp at Wells Fargo Healthcare Conference Transcript
Feb 10, 2024 14:23pm

Glaukos Corp at Wells Fargo Healthcare Conference Transcript


Source:GuruFocus
Glaukos Corp''s President & COO Joseph Gilliam Sells 9,476 Shares
Feb 01, 2024 20:01pm

Glaukos Corp''s President & COO Joseph Gilliam Sells 9,476 Shares


Source:GuruFocus